-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Sector Analysis
NewCell and Gene Therapies in Hemophilia A and B – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies (CGT) in Hemophilia A and B Market Report Overview The hemophilia A and B CGT market reached $12 million in 2023 with massive expansions across therapeutic areas. The CGT in Hemophilia A and B market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in Hemophilia A & B including launch date projections, key clinical trial analysis, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Gastrointestinal Stromal Tumor (GIST) Drug Details: Bezuclastinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Systemic Mastocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Systemic Mastocytosis Drug Details: Bezuclastinib (CGT-9486) is under development for...
-
Thematic Analysis
State of the Biopharmaceutical Industry in 2024 – Thematic Intelligence
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you in: Examining the current attitudes of business leaders toward the emerging trends impacting the biopharmaceutical industry in the next 12 months. Benchmarking the impact of major themes on the biopharmaceutical industry in 2024, including emerging technologies, regulatory trends, macroeconomic trends, and industry trends. Identifying the most impactful anticipated regulatory approvals and drug launches in the industry in 2024, learning about top-selling drugs (2023 vs 2024), and obtaining...
-
Sector Analysis
Ovarian Cancer – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Ovarian Cancer Cell and Gene Therapy Market Report Overview Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type. Most clinical cases are epithelial ovarian cancers, which represent approximately 90% of diagnosed patients. Ovarian Cancer cell and gene therapy (CGT) market research includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies...
-
Sector Analysis
Melanoma – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Melanoma Cell and Gene Therapy Market Report Overview Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin. While the underlying causes remain unclear, several risk factors that increase the chance of developing melanoma have been identified. Ultraviolet light exposure is considered the leading risk factor for melanoma because UV rays can cause DNA damage to skin cells. The main sources of UV rays are sunlight...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Non-Small Cell Lung Cancer Market Report Overview The non-small cell lung cancer (NSCLC) market size for the 15 markets (15M) was $30.7 billion in 2021. This included both Cell & gene therapies (CGTs) and established/traditional therapies. Cell therapies, consisting mostly of tumor-infiltrating lymphocytes (TILs) and CAR-T cells, are the most-abundant modality type in the NSCLC CGT pipeline but fall far behind traditional therapies such as monoclonal antibodies and small molecules. The non-small cell lung cancer market research report includes an...
-
Sector Analysis
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Glioblastoma Multiforme Market Report Overview The Glioblastoma Multiforme market value for the 15 markets (15M) was $630 million in 2021. This included both CGTs and established/traditional GBM therapies. The Glioblastoma Multiforme market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for...